GHK vs GHK-Cu: How Copper Coordination Changes a Tripeptide

Open a research-chemical catalog and you'll often find GHK and GHK-Cu listed a line apart, as though the copper were a formatting detail. It isn't. Both materials are supplied for research use only, and both are built from the same three amino acids — but one carries a metal ion, and that ion changes the molecular formula, the net charge, the shape of the molecule, and what it does in a culture dish. If you're researching this tripeptide, that's the distinction worth getting straight first. The literature doesn't treat the two forms as interchangeable, even where product listings imply they are.

What follows: what the free peptide is, what the copper adds structurally, why the reported binding constant is the most interesting number in the field, how chelation changes copper's reactivity, and what the peptide does with no metal attached at all.

Two names, one sequence, two different molecules

GHK and GHK-Cu aren't two labels for one compound. They're a peptide and a metal complex of that peptide, and they differ on paper long before they differ in any assay.

The sequence itself

GHK is glycyl-L-histidyl-L-lysine — glycine, then L-histidine, then L-lysine, in that order. The free tripeptide has the molecular formula C₁₄H₂₄N₆O₄ and a molar mass of 340.38 g/mol. Three residues is small even by peptide standards, and the smallness matters: a tripeptide presents its donor atoms to a metal ion in one tidy arrangement, without the folding that complicates metal binding in larger proteins.

Loren Pickart isolated the copper form from human plasma albumin in 1973. What started it was a biological observation, not a chemical one — older liver cells behaved more like younger tissue when exposed to serum from younger donors. The active fraction eventually resolved to a small peptide matching the synthetic Gly-His-Lys sequence, confirmed by 1977.

What the copper form looks like on paper

The complex is written C₁₄H₂₂CuN₆O₄. Same carbon skeleton, same six nitrogens, same four oxygens — plus one copper, and two fewer hydrogens. That hydrogen deficit is the chemical signature of coordination: nitrogen atoms that were carrying protons give them up to bind the metal. A species with a different formula, charge, and solution behavior is a different compound, whatever the shared sequence suggests.

Peptide research is full of naming collisions that mislead this way — our write-up on two peptides that share a name but not a structure covers a case where the label hides a far larger gap. GHK is the subtler version. Here the sequence genuinely is identical, and only the metal differs.

How the copper actually sits in the complex

The copper isn't loosely attached to the outside of the peptide. It's held by a specific, identified set of donor atoms, and that set is what defines the complex.

The donor atoms

Structural work describes three nitrogen donors around the Cu(II) ion: the histidine imidazole nitrogen, the alpha-amino nitrogen of the terminal glycine, and the deprotonated amide nitrogen of the glycine-histidine bond. Carboxyl contribution from the neighboring lysine completes the picture, producing what the literature calls a square-planar-pyramidal configuration. Related work on GHK and carnosine as copper-binding peptides describes the same essentials, and notes that the lysine side-chain amino group offers a further coordination option when the peptide is derivatized. For the full structural treatment rather than the comparison, start with the coordination chemistry of GHK-Cu in detail.

Carrier, not cage

Here's the distinction that drives the whole comparison: GHK doesn't merely sequester copper and sit on it. The same work describes both GHK and the dipeptide carnosine as copper ionophores — species that move the metal across membranes rather than pulling it out of circulation. That's a different job from a conventional chelator, and it's why the two forms read better as two points in one equilibrium than as a compound and its inactive precursor.

Carnosine is the useful contrast. At physiological pH its copper complex settles into a 2N(imidazole), 2O(carboxylate) mode — a different donor set around the same metal, with a different functional profile. Same element, different cradle, different chemistry. Geometry at this scale comes from crystallography and solution-phase spectroscopy rather than inference; on the latter, see how peptide structures get solved in solution.

Binding strength is the interesting number

The headline figure in the GHK literature isn't how tightly the peptide grips copper. It's how deliberately middling that grip turns out to be.

A 2026 systematic review puts the binding constant at approximately log K = 16.44 at physiological pH, and reads it this way: high enough that the complex "remains intact during transport but exchangeable enough that copper can be released to high-affinity intracellular acceptors." An unusual place to land. A far larger constant would lock the metal away; a much smaller one would surrender it.

And there's plenty else in solution to surrender it to. Plasma copper isn't free-floating; albumin's N-terminal Asp-Ala-His site and ceruloplasmin both bind it, and the same review describes GHK as protecting copper from non-specific binding to both — a claim about competition, not about affinity in isolation. Speciation data backs that framing. In cell-free work cited in a 2024 study of GHK's interaction with copper and zinc in CNS cell models, 5 mM GHK combined with human serum albumin and Cu²⁺ shifted more than 40% of detected copper species into binary Cu-GHK and ternary GHK-containing complexes. GHK doesn't simply lose the contest with albumin — it forms mixed species alongside it. All of this is solution chemistry measured in vitro. It describes a tube and cultured cells, not an outcome in a person.

What chelation changes about copper's reactivity

Binding copper quiets it down. Published data says it doesn't switch it off.

The redox question

Copper is useful and hazardous for the same reason. It moves readily between Cu(II) and Cu(I), which is what makes it an electron-transfer cofactor across the cuproenzymes governing cellular respiration, antioxidant defense, and connective-tissue formation — and also what lets loose copper drive Fenton-type radical chemistry. A genome-focused review of GHK-Cu frames the peptide's small size and copper affinity as precisely what lets it participate in copper metabolism rather than merely interfere with it.

The structural argument for why chelation calms the metal runs like this: carboxylate and imidazole ligands build a sphere that thermodynamically favors Cu(II), limiting how readily copper switches oxidation states under physiological conditions. Sequestering the metal, as the comparative work puts it, without entirely removing its biological functionality.

That tidy picture has been contested, and the contest is informative. The 2024 CNS study reported the GHK-Cu complex still formed reactive oxygen species in solution — significantly below free Cu²⁺, but not at zero. Their own data went further: GHK at up to 1000 µM against 500 µM Cu²⁺, a 2:1 molar ratio, couldn't fully block the ROS increase. Chelation dampens. It doesn't silence.

Sequestration, not scavenging

The same study separates two mechanisms that are easy to conflate. GHK showed no capacity to act on the DMPD radical cation at physiologically relevant concentrations, which argues against direct free-radical scavenging and for metal sequestration as the route behind the protective effects observed. In cell culture those effects were real: viability losses in BV2 microglia and primary cerebellar neurons exposed to 500 µM Cu²⁺ were partially rescued by GHK, and in cell-free assays excess GHK both blocked copper- and zinc-induced BSA aggregation and resolubilized aggregates that had already formed.

Copper as catalyst, not just cargo

None of which makes the metal half decorative. Cu(II) is the obligate cofactor of the lysyl oxidase family — LOX and LOXL1 through LOXL4 — whose lysine-tyrosylquinone cofactor is itself generated by copper-catalyzed oxidation of an active-site tyrosine. The systematic review is blunt: without adequate copper at that site, newly synthesized collagen molecules "remain unlinked, mechanically weak, and susceptible to proteolytic degradation." Delivering copper and stimulating collagen synthesis aren't the same thing, and only one of them requires the metal.

What the free peptide does without the metal

If copper delivery were the whole story, copper-free GHK should do nothing on its own. That isn't what the data shows.

Metal-independent activity

The systematic review cites work by Choi and colleagues in which copper-free GHK reproduced several effects previously credited to the complex, with both forms elevating p63 and integrin expression in basal keratinocytes — evidence the peptide backbone carries signaling activity of its own. A 2022 review in the International Journal of Molecular Sciences adds that free GHK quenches cytotoxic lipid-peroxidation end products and brought hydrogen-peroxide-induced ROS down to roughly 60% of control.

The broadest argument against a copper-only model is transcriptional. Connectivity Map analysis attributed a 50%-or-greater expression change in roughly 31.2% of human genes to GHK — 59% upward, 41% downward — including 41 ubiquitin-proteasome genes up against a single one down. The authors say the quiet part out loud: attributing GHK's effects to copper binding alone "doesn't explain the gene modulating effects."

Where the complex still comes out ahead

Reviews that put the two forms side by side are consistent on potency. The 2022 review concludes that compared with GHK, the copper(II)-chelated form shows a more prominent antioxidant and anti-inflammatory profile in both in-vitro and in-vivo models — in macrophage culture, GHK-Cu pretreatment lowered lipopolysaccharide-induced ROS while suppressing NF-κB p65 and p38 MAPK signaling, with correspondingly lower TNF-α and IL-6 expression. At 1 nanomolar it raised bFGF and VEGF expression in angiogenesis models. So the honest framing is a difference of degree and context — not of active versus inert.

Practical chemistry notes for a bench comparison

The two forms behave differently in a vial, not only in an assay, and a careless side-by-side can hand you a misleading answer.

Stability first. GHK-Cu is highly sensitive to cleavage by carboxypeptidase enzymes and degrades rapidly in weakly acidic conditions, so pH-dependent speciation is a live variable rather than a footnote.

Then the shape of the concentration-response, which is biphasic rather than linear. In fibroblast culture, nanomolar GHK-Cu raised collagen and elastin output while higher concentrations attenuated or inverted the effect; TIMP1 rose at every concentration tested, but MMP1 and MMP2 only at the lower ones. Comparing the two forms at one arbitrary concentration can land on either side of that inflection and tell you very little. Salt form is the third confound — see our note on how counterions and salt form can skew a cell assay.

And the baseline is never zero. GHK is a matricryptin liberated from SPARC and collagen I-alpha-2 during matrix proteolysis, so both forms are already present endogenously in any system under study.

Frequently Asked Questions

Is GHK the same thing as GHK-Cu?

No. GHK is the free tripeptide glycyl-L-histidyl-L-lysine, C₁₄H₂₄N₆O₄, 340.38 g/mol. GHK-Cu is that same sequence with a Cu(II) ion chelated into it: C₁₄H₂₂CuN₆O₄. The two missing hydrogens aren't a typo — they reflect deprotonation of the nitrogens that coordinate the metal. These are two different chemical species with different charge, geometry, and solution behavior, and they aren't interchangeable in a research setting.

What does the binding constant log K = 16.44 actually mean?

It measures how tightly GHK holds a Cu(II) ion at physiological pH, on a logarithmic scale. Reviews read the value as sitting in an unusual middle zone — strong enough that the complex survives transport through a protein-rich medium, weak enough that copper can still be handed off to higher-affinity acceptors. That dual property is why the literature calls GHK a copper carrier rather than a copper sink.

Does binding copper to GHK make the metal chemically inert?

Not completely. Chelation lowers copper's redox activity substantially, but a 2024 in-vitro study reported the GHK-Cu complex still generated reactive oxygen species in solution — well below free Cu(II), but not zero. In the same work, GHK at a 2:1 molar ratio against copper (1000 µM against 500 µM Cu²⁺) did not fully suppress the ROS increase. Coordination dampens the metal's reactivity rather than silencing it.

Does copper-free GHK do anything on its own?

Published work suggests yes. In keratinocyte models, copper-free GHK reproduced several effects previously credited to the complex, with both forms elevating p63 and integrin expression. Genome-wide analysis attributed a 50%-or-greater expression change in roughly 31.2% of human genes to GHK, and its authors argued that copper delivery alone cannot account for that breadth. Reviews comparing the forms directly still report the copper-bound complex as the more potent in antioxidant and inflammatory assays.

Why do both forms appear in human tissue naturally?

GHK is a matricryptin — a short bioactive fragment liberated when extracellular-matrix proteins are broken down, released from SPARC and collagen I-alpha-2 during proteolysis after injury and detectable in plasma, saliva, and urine. Because plasma copper is abundant and GHK's affinity for it is high, the free peptide and the complex coexist as an equilibrium rather than as separate compounds. Measured plasma GHK falls from roughly 200 ng/mL at age 20 to about 80 ng/mL by 60.

What the Comparison Actually Tells You

The copper isn't a garnish on GHK. It changes the formula, the charge, the coordination geometry, and — in reviews that run the comparison directly — the measured potency. But the peptide backbone isn't inert scaffolding either. Copper-free GHK has its own documented activity in keratinocyte and ROS assays, and the breadth of the gene-expression response is hard to explain by metal delivery alone.

Where the field stands, plainly: most published work characterizes the copper complex, far fewer studies run both forms side by side at matched concentrations, and the biphasic concentration-response makes single-point comparisons unreliable.

For research use only. Not for human or animal consumption of any kind. The information in this article is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The statements made have not been evaluated by the U.S. Food and Drug Administration. These products are NOT FDA APPROVED. Please consult with a licensed healthcare professional before making any decisions regarding your health or research.

Optides LLC is a chemical supplier. Optides LLC is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. Optides LLC is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic Act.